New combo therapy shows promise for rare blood cancer
NCT ID NCT04127227
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. The treatment combines an immunotherapy drug (sintilimab) with a chemotherapy regimen (P-GemOx). The goal is to see if this combination is safe and effective at shrinking or eliminating tumors. The study involves 34 adults who have not received prior treatment for their advanced disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK/T CELL LYMPHOMA NOS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 51000, China